Some examples and use cases from the internet:

Some examples and use cases from the internet:

• Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Myfenax, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
• Patients receiving immunosuppressive regimens involving combinations of medicinal products, including CellCept, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
• Patients with underlying neurological disorders including swallowing difficulties are at increased risk of these side effects.
• Patients receiving zidovudine in combination with ribavirin and alpha interferons are at increased risk of developing anaemia.
• Neoplasms benign, malignant and unspecified (incl cysts and polyps) Patients receiving immunosuppressive therapy are at increased risk of developing malignancies.
• Patients with underlying neuromuscular disorders including swallowing disorders are at increased risk of these undesirable effects.
• Neoplasms benign, malignant and unspecified Patients receiving immunosuppressive therapy are at increased risk of developing malignancies.
• Children under five who live near nuclear power stations run an increased risk of contracting cancer.

• Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
• Your doctor has prescribed this medicine for you because after an operation you are at an increased risk of getting blood clots.
• Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk of severe and potentially fatal hepatic adverse events.
• IDflu is used to vaccinate adults against flu, especially those who are at an increased risk of developing complications of the disease.
• Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
• Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.
• Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
• Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.